Literature DB >> 14635053

Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients.

Monica Colombo1, Mariella Dono, Paola Gazzola, Nicholas Chiorazzi, Gianluigi Mancardi, Manlio Ferrarini.   

Abstract

A longitudinal study of Ig V gene segments utilized by B cells from the cerebrospinal fluid (CSF) of two patients with multiple sclerosis (MS) was carried out using RT-PCR methodologies. One patient with a relapsing-remitting (RR)-MS was investigated at onset and at relapse, 1 year later. A patient with secondary-progressive (SP)-MS was tested 9 and 13 years after disease onset. Sequence analyses of V(H)DJ(H) segments bearing V(H)3 and V(H)4 that were obtained from Cgamma cDNA genes demonstrated a substantial proportion of shared clones in the samples taken at different times; these clones were identical or closely related, i.e. had the same third complementary determining region (CDR) of the H chain variable region gene (HCDR3) with different mutations in the V(H) segment. Collectively, these data demonstrate that in MS patients there is a strong selective pressure, which could be exerted by antigen (or autoantigen) stimulation, for the maintenance and partial diversification of certain V(H)DJ(H) Cgamma sequences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635053     DOI: 10.1002/eji.200324144

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

2.  Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis.

Authors:  Ariele L Greenfield; Ravi Dandekar; Akshaya Ramesh; Erica L Eggers; Hao Wu; Sarah Laurent; William Harkin; Natalie S Pierson; Martin S Weber; Roland G Henry; Antje Bischof; Bruce Ac Cree; Stephen L Hauser; Michael R Wilson; H-Christian von Büdingen
Journal:  JCI Insight       Date:  2019-03-21

3.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

4.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis.

Authors:  Sabine Cepok; Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Susanne Stei; Konrad Büssow; Norbert Sommer; Bernhard Hemmer
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

5.  Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Authors:  Jan D Lünemann; Mar Tintoré; Brady Messmer; Till Strowig; Alex Rovira; Héctor Perkal; Estrella Caballero; Christian Münz; Xavier Montalban; Manuel Comabella
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 6.  Epstein-Barr virus and multiple sclerosis.

Authors:  Jan D Lünemann; Christian Münz
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

7.  Cerebrospinal-fluid-derived immunoglobulin G of different multiple sclerosis patients shares mutated sequences in complementarity determining regions.

Authors:  Vaibhav Singh; Marcel P Stoop; Christoph Stingl; Ronald L Luitwieler; Lennard J Dekker; Martijn M van Duijn; Karim L Kreft; Theo M Luider; Rogier Q Hintzen
Journal:  Mol Cell Proteomics       Date:  2013-08-22       Impact factor: 5.911

Review 8.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.